- Senior Scientist, Genetics & Genome Biology
- MD, PhD
- 416-813-7654 ext. 308980
- Alternate Contact Name:
- Shiva Yaghini
- Alternate Email:
- U of T Positions:
- Professor, Departments of Paediatrics and Molecular Genetics
- Chair Positions:
- Mogford Campbell Family Chair of Paediatric Neurosciences
Division of Neurology
Dr. James Dowling is a clinician-scientist focused on gene discovery and therapy development for childhood muscle diseases. Dr. Dowling received his B.Sc. and M.Sc. from Yale University and his MD/PhD from the University of Chicago. His PhD work was performed in the laboratory of Elaine Fuchs. He did his residency in child neurology at Children’s Hospital of Philadelphia and completed postdoctoral research with Jeff Golden (UPenn) and Eva Feldman (University of Michigan). Before coming to Toronto, he was an assistant professor at the University of Michigan from 2009-2013.
Dowling’s clinical expertise is in childhood neuromuscular disorders and he is considered one of the leading authorities on the diagnosis and management of congenital myopathies. His research examines questions of disease pathogenesis and therapy development for congenital myopathies and childhood muscular dystrophies. He has authored or co-authored more than 100 peer reviewed manuscripts and been fortunate to enjoy funding from several sources, including CIHR, NIH, MDA, and Genome Canada.
The overall goal of Dowling's research program is to discover therapies for childhood muscle diseases. He is particularly focused on muscle disorders that present in infancy, including the congenital myopathies and the congenital muscular dystrophies. Dowling utilizes a combinatorial approach that includes new gene discovery (using next generation sequencing technology), model organism development (particularly using the zebrafish model system) and both targeted, and large scale screening drug discovery approaches. He complements this work with cutting edge rare disease clinical research related to natural history, outcome measure development, and interventional trials.
Education and experience
- 1989–1993: Undergraduate, Yale University
- 1993–2001: MD, PhD, University of Chicago
- 2001–2002: Internship, Pediatrics, University of Chicago Children’s Hospital
- 2002–2005: Residency, Child Neurology, Children’s Hospital of Philadelphia
- 2005–2006: Fellow, Neuromuscular Medicine and Neurogenetics, University of Michigan
- 2006–2009: Instructor, Pediatrics, Postdoctoral Fellow, Neurology, University of Michigan
- 2009–2013: Assistant Professor, Pediatrics (Division of Neurology), University of Michigan
- 2013–present: Staff Clinician and Senior Scientist, Division of Neurology, Hospital for Sick Children
- 2013–2015: Assistant Professor, University of Toronto
- 2015–2020: Associate Professor, University of Toronto
- 2020–present: Professor, University of Toronto
- 2016: Junior Physician Researcher Award – Department of Paediatrics, University of Toronto
- 2016–present: Mogford Campbell Family Chair of Paediatric Neurosciences – Hospital for Sick Children
- 2018–present: Chair – Canadian Paediatric Neuromuscular Group
- 2019–present: Executive Committee – World Muscle Society
- 2020–present: Vice Chair – TREAT NMD
- Maani N, Sabha N, Rezai K, Ramani A, Groom L, Eltayeb N, Mavandadnejad F, Pang A, Russo G, Brudno M, Haucke V, Dirksen RT, Dowling JJ. (2018). Tamoxifen therapy in a murine model of myotubular myopathy. Nature Communications doi: 10.1038/s41467-018-07057-5. PMID: 3045184. IF: 12.35. Significance: This study is the first to demonstrate pre-clinical efficacy of tamoxifen for myotubular myopathy, a severe disorder without current treatment. The results are immediately translatable, and a clinical trial is funded and planned based on these data.
- Amburgey K, Tsuchiya E, de Chastonay S, Glueck M, Alverez R, Nguyen CT, Rutkowski A, Hornyak J, Beggs AH, Dowling JJ. (2017). A natural history study of X-linked myotubular myopathy. Neurology. Sep 26;89(13):1355-1364. doi: 10.1212/WNL.0000000000004415. (SRA)
IF: 8.32. Featured with an accompanying editorial.
Significance: This study represents the first natural history study of myotubular myopathy, and identifies key elements of the clinical course of disease and novel outcome measures.
- Sabha N., Volpatti JR, Gonorazky H, Reifler A, Davidson AE, Li X, Eltayeb NM, Dall’Armi C, Di Paolo G, Brooks SV, Buj-Bello A, Feldman EL, Dowling JJ. (2016). PIK3C2B inhibition improves function and prolongs survival in myotubular myopathy animal models. Journal of Clinical Investigation. Sep 1;126(9):3613-25. doi: 10.1172/JCI86841 (SRA)
IF: 12.575. Recommended by Faculty of 1000.
Significance: Using both zebrafish and murine models, this study identified the first genetic modifier of myotubular myopathy, and utilized this knowledge to uncover the first potential small molecule therapeutic for this disease.
- Amburgey K, McNamara N, Bennett LR, McCormick ME, Acsadi G, and Dowling JJ. (2011). Prevelance of congenital myopathies in a representative pediatric United States population. Annals of Neurology DOI: 10.1002/ana.22510. (SRA)
Significance: This manuscript reports the first systematically obtained prevalence data for congenital myopathies for any country or region.
- Dowling JJ, Vreede AV, Low SE, Gibbs EM, Bonnemann CG, Kuwada JY, and Feldman EL. (2009). Loss of myotubularin function results in T-tubule disorganization in zebrafish and human myotubular myopathy. PLoS Genetics 5(2):e1000372. (PA).
IF: 8.517. Recommended article by Faculty of 1000
Significance: This paper reports the first association between myotubularin dysfunction and excitation-contraction coupling abnormalities. It represents a paradigmatic shift in the understanding of the pathogenesis of centronuclear myopathies. The article been cited more than 150 times.
- 2019–2022: Co-PI, Network Catalyst Grant “NMD4C”. (PI, Lochmuller) Canadian Institutes of Health Research (CHIR).
- 2019–2024: PI, Novel gene based therapy for nemaline myopathy. National Institutes of Health (NIH) R01
- 2018-2022: Co-PI, C4R-SOLVE GC LSARP Act 1,2,3. (PI, Boycott) Funds from Genome Canada and MRIS.
- 2018–2020: PI, Micro RNAs as biomarkers and therapeutic targets in myotubular myopathy. National Institutes of Health (NIH) R21
- 2018–2023: Co-PI (w/ Shlien), RNAseq as a clinical diagnostic test for rare disease and childhood cancer, Genome Canada Disruptive Innovations in Genomics (DIG) grant,
- 2018–2020: PI, Combinatorial Therapy as a Novel Treatment Strategy for Myotubular Myopathy. Myotubular Trust/ Great Ormond Street Hospital Children’s Charity
- 2017–2021: PI, MTMopathies: Novel therapies for neuromuscular diseases with altered phosphoinositide metabolism. E-RARE JTC 2017, Canadian Institutes of Health Research and Muscular Dystrophy Canada
- 2017–2022: PI, Therapy Development for Myotubular Myopathy and Related Disorders. Canadian Institutes of Health Research, CIHR. Project grant
- 2017–2026: Endowment-Co-PI (with Justice) Canadian Gene Cure Foundation Legacy Fund SickKids Gene Cure Advanced Therapies for Rare Diseases, CanGARD
- 2016–2021: PI, Unraveling the Genetics of Malignant Hyperthermia. Canadian Institutes of Health Research, CIHR. Project Grant
- 2015–2021: PI, Phosphoinositide Metabolism and its Role in Skeletal Myogenesis. Operating Grant. NSERC